A causative association was recently demonstrated between homozygous TREM2 mutations and frontotemporal dementia (FTD)-like syndrome and between heterozygous TREM2 exon2 genetic variations and late-onset Alzheimer's disease (AD). The objective of this study was to evaluate whether heterozygous TREM2 genetic variations might be associated to the risk of FTD. TREM2 exon 2 was sequenced in a group of 1030 subjectsdnamely, 352 patients fulfilling clinical criteria for FTD, 484 healthy control subjects (HCs), and 194 patients with AD. The mutation frequency and the associated clinical characteristics were analyzed. We identified 8 missense and nonsense mutations in TREM2 exon 2 in 24 subjects. These mutations were more frequent in patients with FTD than in HCs (4.0% vs. 1.0%, p ¼ 0.005). In particular, TREM2 Q33X, R47H, T66M, and S116C mutations were found in FTD and were absent in HCs. These mutations were associated with either the semantic variant of primary progressive aphasia or the behavioral variant FTD phenotypes. The FTD and AD groups were not significantly different with regard to TREM2 genetic variation frequency (AD: 2.6%, p ¼ 0.39). Heterozygous TREM2 mutations modulate the risk of FTD in addition to increasing susceptibility to AD. Additional studies are warranted to investigate the possible role of these mutations in the pathogenesis of neurodegenerative disorders.
Introduction
Frontotemporal dementia (FTD) is a heterogeneous neurodegenerative disorder characterized by behavioral disturbances, language impairment, and deficits in executive functions . On the basis of presenting clinical symptoms, the behavioral variant of FTD (bvFTD), agrammatic variant of primary progressive aphasia, and semantic variant of primary progressive aphasia (svPPA) represent the most common phenotypes (Gorno-Tempini et al., 2011; Rascovsky et al., 2011) .
FTD has a strong genetic background, as suggested by positive family history in almost 40% of patients, and several monogenic forms of FTD have been identified. Mutations within microtubule-associated protein tau (MAPT) and granulin (GRN) genes along with repeat expansion of C9orf72 gene represent the most frequent causes of autosomal dominant inherited disorder (Rademakers et al., 2012; Rohrer et al., 2011) . Despite a giant step forward in the knowledge of genetic bases of FTD, several cases even with positive family history remain of unknown pathogenesis. The identification of new genetic predisposing factors, even rare variants, is key to further elucidating the pathogenetic mechanisms leading to frontotemporal brain damage.
Homozygous loss-of-function mutations in TREM2,e n c o d i n gt h e triggering receptor expressed on myeloid cells 2 protein, have been previously associated with an autosomal recessive form of early-onset dementia presenting with bone cysts and consequent fractures called polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, or Nasu-Hakola disease (Paloneva et al., 2000 (Paloneva et al., , 2002 . Interestingly, it has been reported that homozygous TREM2 exon 2 mutations may resemble FTD clinical phenotype without any bone-associated symptoms (Guerreiro et al., 2013a) . Nevertheless, heterozygosis of TREM2 exon 2 mutations also has a role in neurodegenerative disorders because it has recently been associated with increased risk of late-onset Alzheimer'sdisease(AD) (Guerreiro et al., 2013b; Jonsson et al., 2013) .
These observations defined the aim of the present study, and we hypothesized that variations within TREM2 gene might be associated with a broader clinical spectrum and might predispose to FTD phenotype in heterozygous state. We evaluated genetic variations within TREM2 exon 2 gene in a large cohort of patients with FTD, compared with healthy control subjects and a group of patients with AD.
Methods

Subjects
Patients fulfilling revised criteria for FTD (Gorno-Tempini et al., 2011; Rascovsky et al., 2011) were consecutively recruited from the Center for Aging Brain and Neurodegenerative Disorders, University of Brescia, the Neurology Unit, University of Florence, and the Neurology Unit, University of Milan, Italy.
All subjects underwent a somatic and neurologic evaluation, routine laboratory examination, and brain structural imaging study. A standardized neuropsychological assessment including global cognitive evaluation and a standardized neuropsychological test battery for investigating the main cognitive domains was performed. The diagnostic assessment included a review of full medical history, a semistructured neurologic examination, and a complete mental status evaluation. Patients considered to have a positive family history were those who had a first-degree relative with dementia, parkinsonism, or motor neuron disease. No patients belonging to the same family were included. A venous blood sample was drawn from each patient for TREM2 exon 2 sequencing.
Patients with MAPT or GRN mutations and with repeat expansion of C9orf72 gene were excluded (Borroni et al., 2011; Galimberti et al., 2013) . Moreover, a control group similar in age and gender composition was recruited in the same Italian area from which the patients were drawn and was sequenced for TREM2 exon 2 genetic variations. Two subgroups were considered for comparisons, that is, subjects found to be cognitively intact, following medical history, presence of comorbidities, and neuropsychological examination (healthy controls [HCs] ), and patients fulfilling clinical diagnosis of AD according to current criteria (McKhann et al., 1984) .
Informed consent was obtained for blood collection from venous puncture and genetic analysis from each subject. The work conform to the Helsinki Declaration and was approved by the ethics committee of our hospital.
TREM2 exon 2 sequencing
Total genomic DNA was prepared from peripheral blood according to standard procedures. TREM2 exon 2 and at least 100 base pairs of its flanking introns were evaluated by polymerase chain reaction (PCR), the primers of which were designed to optimize denaturing high-performance liquid chromatography (dHPLC) conditions (forward primer: 5 0 -CACAGAGCAAGTGTTCAAAGC-3 0 and reverse primer: 5 0 -CACACAGACGCCCAAAAC-3 0 with the annealing temperature of 57 C.
Preliminary dHPLC analysis was performed on the Wave nucleic acid fragment analysis system (Transgenomic, Santa Clara, CA, USA), and samples with an altered dHPLC profile were sequenced. Nucleotide direct sequencing was performed on genomic DNA for both strands by ABI 3130xl DNA analyzer (Applied Biosystems, Foster City, CA, USA) and analyzed using SeqScape Software version 2.6 (Applied Biosystems, Foster City, CA, USA).
Bioinformatic analyses
A multiple protein alignment was constructed with multiple alignment by Bioedit (http://www.mbio.ncsu.edu/bioedit/bioedit. html) and CLUSTALW (http://clustalw.ddbj.nig.ac.jp/top-e.html) software.
The potential effect of the newly detected mutations on protein structure or function was analyzed with 4 prediction programs: PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/), Pmut: (http://mmb.pcb.ub.es/PMut/), SNAP (http://rostlab.org/services/ snap/), and SIFT (http://sift.jcvi.org/www/SIFT_enst_submit.html).
Statistical analysis
Comparisons of each mutation and overall mutation frequencies between patients and HCs were compared by Pearson c 2 test. Logistic regression analysis was performed to assess odds ratio, and corresponding 95% confidence intervals. Results are expressed as mean AE SD or percentage, as reported. The significant level was established at p < 0.05. Data analyses were carried out using SPSS 13.0 software (http://wwwspss.com).
Results
One thousand and thirty subjects were included in the present study, 352 patients with a diagnosis of FTD (aged 65.6 AE 8.6 years, 48.8% women), and, as control groups, 484 HCs (aged 72.2 AE 10.1 years, 54.5% women) and 194 patients with AD (aged 65.9 AE 7.2 years, 53.1% women).
In the overall sample, we found 8 genetic variations in 24 subjects in 24 subjects: Q33X, R47H, R62H, T66M, D87N, T96K, R98W, and S116C. As reported in Table 1 , R47H, T66M, and S116C were found only in patients with FTD; Q33X was found in patients with both FTD and AD, and R62H, D87N, T96K, and R98W were also found in HCs. Overall, we found significantly more variants in exon 2 of TREM2 in patients with FTD than in HCs (4.0% vs. 1.0%, p ¼ 0.005). Carriers of TREM2 exon 2 mutations had an almost 4-fold increased risk to develop FTD than noncarriers (odds ratio: 3.97, 95% confidence intervals: 1.42e11.12). In FTD, 6 of 14 patients carried heterozygous TREM2 mutations that were not found in HCs. As reported in Table 2 , in silico analysis demonstrated that the Q33X variant (cytosine to thymine change in position 6818), previously associated with Nasu-Hakola disease in the homozygous state, resulting in a TAG stop codon with a loss of function of the TREM2 protein.
The R47H mutation was characterized by a single point mutation in the CGC codon, with the substitution of guanine with adenine, and was predicted to be damaging in 3 of 4 in silico analyses. The T66M mutation was characterized by a single point mutation in the ACG codon, resulting in a replacement of threonine at position 66 with methionine; all in silico analyses predicted a pathologic effect of this substitution, and this mutation was previously associated with Nasu-Hakola disease in homozygosity. S116C has not been previously described in the literature and causes a substitution of adenine to thymine; no clear-cut results were obtained by in silico analysis because 2 of 4 prediction analyses suggested neutral effect.
In Table 3 , demographic and clinical characteristics of patients with FTD carrying TREM2 Q33X, R47H, T66M, and S116C are reported. In most of these cases, patients presented an early age of onset (range: 52e68 years), and 66.7% were women. Family history was unremarkable in 5 of 6 patients. Half had a diagnosis of svPPA (2 Q33X, 1 S116C), and the others had a diagnosis of bvFTD (1 Q33X, 1 R47H, and 1 T66M), with a phenotypic variability in patients carrying the same genetic variation.
When the AD control group was considered to elucidate whether FTD and AD may share a common at-risk genetic background, no significant differences in the overall number of TREM2 exon 2 mutations were found (4.0% vs. 2.6, p ¼ 0.46). Notably, in 1.5% of patients with AD (n ¼ 3, 2 women, age range 58e69 years), a heterozygous Q33X mutation was found, whereas 1 patient carried R62H and 1 carried R98W, both of which were also found in HCs.
Finally, when the AD group was compared with the HC group, we found significantly more Q33X variants of TREM2 in the former group (n ¼ 3, 1.5%) then the latter (0.0%, p ¼ 0.023). Patients with AD carrying Q33X mutation showed late-onset disease (aged 65e75 years), 2 of 3 were women, and none carried the apolipoprotein E ε4 allele.
Moreover, in AD, we found R62H and R98W mutations, which were detected in HCs as well. We did not find any difference in overall frequency of mutations in patients with AD versus HCs, presumably because of the small sample of patients with AD.
Discussion
TREM2 gene has recently gained great interest in the dementia field, as the identification of homozygous mutations in cases of FTDlike phenotype (Guerreiro et al., 2013a (Guerreiro et al., , 2013c , and the demonstration that TREM2 exon 2 genetic variations are risk factors for AD in heterozygosis (Guerreiro et al., 2013b; Jonsson et al., 2013) . With these premises, we hypothesized that heterozygous TREM2 mutations might be related to FTD risk as well. In the present work, we screened a large sample of patients and HCs for TREM2 exon 2 genetic variations and found that FTD patients showed increased frequency of heterozygous TREM2 mutations compared with HCs. Interestingly, we confirmed that Q33X, R47H, and T66M mutations were significantly associated with the disease and absent in healthy subjects. Q33X and T66M mutations have previously been demonstrated to cause Nasu-Hakola disease in the homozygous state (Paloneva et al., 2000 (Paloneva et al., , 2002 , and the heterozygous R47H mutation has been associated with AD risk (Guerreiro et al., 2013b; Jonsson et al., 2013) . Accordingly, in silico analysis of these mutations suggested a loss of function in TREM2; this might suggest that these variants are causal mutations, even in heterozygosis, rather than risk factors.
Notably, different clinical phenotypes were observed in FTD patients carrying these TREM2 genetic variations with variable age at disease onset and inconsistent family history for neurodegenerative disorders. Interestingly, patients presented either bvFTD or svPPA, and this is the first association study suggesting a genetic risk factor for svPPA phenotype.
Recently studies on TREM2 genetic variations have been published in France (Lattante et al., 2013) , the United States (Rayaprolu et al., 2013) , and Colombia (Giraldo et al., 2013) with different mutation frequencies. No work exploring the role of TREM2 in the Italian population is available yet.
TREM2 encodes a single-pass type I membrane protein that forms a receptor-signaling complex with the TYRO protein tyrosine kinase-binding protein (TYROBP) that is involved in the activation of immune responses in immune cells, as macrophages and dendritic cells. It is involved in chronic inflammation by triggering the production of constitutive rather than inflammatory chemokines and cytokines and has a critical role in microglia clearance (Neumann et al., 2013; Paloneva et al., 2003; Takahashi et al., 2005) .
Interestingly, we also found TREM2 mutations in our AD patients, confirming previous data (Guerreito et al., 2013b; Jonsson et al., 2013) and suggesting a common pathway in these 2 neurologic disorders, likely associated to inflammation processes. Indeed, emerging evidence has underlined a greater interest in mechanisms targeting inflammation in both diseases Piguet, 2013) . Furthermore, in human control brain, TREM2 was expressed at higher levels in the hippocampus and neocortex (Guerreiro et al., 2013a) , and this pattern of expression is partly consistent with pathologic features observed in both FTD and AD. The effect of TREM2 genetic variations in FTD cases and the possible interaction with protein involved in the known pathogenetic mechanisms of the disease remains to be elucidated. Functional activity assays will be required to determine how these identified mutations might compromise TREM2 function, providing new clues to the mechanisms underlying the pathogenesis of FTD. Unfortunately, we were not able to assess the effect of TREM2 genetic variation in our patients because it is expressed only in microglia and not in circulating monocytes. This is a preliminary study, and we do not exclude the possibility that the frequency of heterozygous mutations we found is partially due to the relatively high number of cases (n ¼ 3) with Nasu-Hakola disease (i.e., homozygous Q33X mutation) that we diagnosed in our geographic area (Bock et al., 2013) . Moreover, it is reasonable to suppose that other mutations in TREM2, beyond exon 2, may be identified. However, as previously suggested (Guerreiro et al., 2013b) , it may be that rare variants in the heterozygous state may be risk factors for late-onset complex disorders, determining defined early-onset disease when in homozygosis.
In conclusion, we report that TREM2 variants might be considered risk variants in FTD not only in homozygosis as previously demonstrated but in heterozygosis as well. Moreover, the absence of certain variants, in both our control population and others previously published (Guerreiro et al., 2013b; Jonsson et al., 2013; Paloeva et al., 2001) , raises the question of whether such variants are mutations leading to dementia and Nasu-Hakola disease rather than polymorphisms influencing the risk of developing FTD. Whether TREM2 is a major gene or a modifier gene for FTD and AD remains to be determined. Future confirmatory clinical and experimental studies are needed to elucidate the role of this gene in FTD.
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